Sulfonamide; aminosalicylate

This page covers all Sulfonamide; aminosalicylate drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 5-aminosalicylic acid (5-ASA) moiety; connective tissue affinity, Prostaglandin G/H synthase 2, Flavin reductase (NADPH).

Targets

5-aminosalicylic acid (5-ASA) moiety; connective tissue affinity · Prostaglandin G/H synthase 2 · Flavin reductase (NADPH) · Cyclooxygenase · JAK1/JAK3 (tofacitinib); unclear specific target for mesalamine (likely prostaglandin-related) · Prostaglandin G/H synthase 1

Marketed (6)

• Azulfidine · Pfizer Inc.
  Anti-inflammatory and immunomodulatory properties, with 5-ASA as major therapeutic moiety in ulcerative colitis.
• Rowasa · Meda Pharms · Oncology
  Rowasa works by blocking the production of prostaglandins, which are chemicals that cause inflammation in the rectum and colon.
• Azulfidine En-Tabs · Pfizer · Immunology
• MESALAMINE · Immunology
  Mesalamine reduces inflammation in the colon by blocking cyclooxygenase and inhibiting prostaglandin production.
• Tofacitinib plus mesalamine · Post Graduate Institute of Medical Education and Research, Chandigarh · Immunology / Gastroenterology
  Tofacitinib inhibits JAK kinases to reduce inflammatory signaling, while mesalamine acts as a topical anti-inflammatory in the colon.
• Colazal · Valeant Pharms Intl · Immunology
  Colazal works by reducing inflammation in the gut by modulating the immune response.

Phase 3 pipeline (1)

• mesalamine granules · Dr. Falk Pharma GmbH · Gastroenterology
  Mesalamine works by releasing aminosalicylates in the colon to reduce inflammation and prevent symptoms of ulcerative colitis.

Patent intelligence

• aminosalicylate patent landscape — aggregated cliff calendar, attackable patents, originator estates